Literature DB >> 15804708

Anti-Jo-1 antibodies.

Sandra Zampieri1, Anna Ghirardello, Luca Iaccarino, Elena Tarricone, Pier Franca Gambari, Andrea Doria.   

Abstract

Anti-Jo-1 antibody is a myositis specific autoantibody most commonly found in patients with idiopathic inflammatory myopathies (IIM). This antibody is directed against the histidyl-tRNA synthetase which catalyses the binding of the histidine to its cognate tRNA during protein synthesis. It can be considered a specific marker of IIM, predominantly found in 20-30% of patients with PM and in the 60-70% of those with interstitial pulmonary fibrosis. These antibodies are also found in DM, although less frequently than in PM, and are rare in children with PM or DM and in other connective tissue diseases.ELISA, CIE and immunoblotting are highly specific and sensitive techniques for testing anti-Jo-1 antibodies. The detection of this antibody is particularly useful in diagnosis and classification of IIM. Moreover, anti-Jo-1 serum levels strongly correlate with disease activity representing a good marker for disease monitoring.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15804708     DOI: 10.1080/08916930400022640

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  14 in total

1.  The olfactory function is impaired in patients with idiopathic inflammatory myopathies.

Authors:  L Iaccarino; N Shoenfeld; M Rampudda; M Zen; M Gatto; A Ghirardello; N Bassi; L Punzi; Y Shoenfeld; A Doria
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Myositis-related interstitial lung disease and antisynthetase syndrome.

Authors:  Joshua Solomon; Jeffrey J Swigris; Kevin K Brown
Journal:  J Bras Pneumol       Date:  2011 Jan-Feb       Impact factor: 2.624

Review 3.  Cutting edge issues in polymyositis.

Authors:  Anna Ghirardello; Sandra Zampieri; Elena Tarricone; Luca Iaccarino; Luisa Gorza; Andrea Doria
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

Review 4.  Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay.

Authors:  Li Wang; Li Huang; Yang Yang; Huan Chen; Yanjuan Liu; Ke Liu; Meidong Liu; Yizhi Xiao; Hui Luo; Xiaoxia Zuo; Yisha Li; Xianzhong Xiao; Huali Zhang
Journal:  Clin Rheumatol       Date:  2018-07-23       Impact factor: 2.980

Review 5.  Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.

Authors:  Linda Nalotto; Luca Iaccarino; Margherita Zen; Mariele Gatto; Elisabetta Borella; Marta Domenighetti; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

6.  A New Immunodot Assay for Multiplex Detection of Autoantibodies in a Cohort of Italian Patients With Idiopathic Inflammatory Myopathies.

Authors:  Marilina Tampoia; Antonella Notarnicola; Letizia Abbracciavento; Antonietta Fontana; Margherita Giannini; Renè Louis Humbel; Florenzo Iannone
Journal:  J Clin Lab Anal       Date:  2016-04-13       Impact factor: 2.352

Review 7.  Differential diagnosis of idiopathic inflammatory myopathies.

Authors:  Alan N Baer
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.686

Review 8.  Myositis autoantibodies and clinical phenotypes.

Authors:  Anna Ghirardello; Elisabetta Borella; Marianna Beggio; Franco Franceschini; Micaela Fredi; Andrea Doria
Journal:  Auto Immun Highlights       Date:  2014-08-23

Review 9.  Autoantibodies in polymyositis and dermatomyositis.

Authors:  Anna Ghirardello; Nicola Bassi; Lavinia Palma; Elisabetta Borella; Marta Domeneghetti; Leonardo Punzi; Andrea Doria
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.686

10.  Biologic predictors of clinical improvement in rituximab-treated refractory myositis.

Authors:  Ann M Reed; Cynthia S Crowson; Molly Hein; Consuelo Lopez de Padilla; Jeannette M Olazagasti; Rohit Aggarwal; Dana P Ascherman; Marc C Levesque; Chester V Oddis
Journal:  BMC Musculoskelet Disord       Date:  2015-09-17       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.